HC Wainwright Has Bullish Estimate for BCRX Q4 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – HC Wainwright upped their Q4 2026 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a report released on Thursday, August 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of $0.18 for the quarter, up from their previous forecast of $0.14. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.44) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. During the same period last year, the business earned $0.15 earnings per share. BioCryst Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year.

Several other equities research analysts have also issued reports on the stock. Needham & Company LLC dropped their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective on the stock. Citizens Jmp boosted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Cantor Fitzgerald upped their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $9.81 on Friday. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.54 and a beta of 0.55. The stock has a fifty day moving average of $9.47 and a 200 day moving average of $8.82. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.22.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its position in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares in the last quarter. Cetera Investment Advisers lifted its stake in shares of BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares in the last quarter. Captrust Financial Advisors raised its holdings in BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 1,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares in the last quarter. Finally, Legato Capital Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 10.0% during the fourth quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 2,172 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.